CSL signs up Thermo Fisher in biologics development and manufacturing deal

CDMO will operate new Swiss facility due for completion in 2021 to support production of next-gen haemophilia product

Under the terms of the agreement, CSL will have access to Thermo Fisher’s pharma services network, including drug product development, biologics manufacturing, sterile fill-finish, packaging and clinical trials logistics.

And through a long-term lease agreement with CSL, Thermo Fisher will operate a new biologics manufacturing facility in Lengnau, Switzerland, when construction is completed in mid-2021.

Within the Lengnau site, Thermo Fisher will support manufacturing of CSL's next-generation product for haemophilia patients. The site will feature flexible bioproduction technologies, including single-use and stainless steel, from development to large-scale production.

Thermo Fisher said it plans to expand the use of the site to include additional biopharma customers.

Michel Lagarde, executive vice president of Thermo Fisher Scientific said the Lengnau facility would significantly expand the firm’s pharma services capacity and capabilities.

“In addition to adding a high-volume production site, we can also address a broadening range of manufacturing needs for our customers, including CSL,” he added.

Paul McKenzie, chief operating officer, CSL, said that as part of the CSL board’s strategic review, the company is in the process of transforming its end-to-end supply chain to ensure its global manufacturing network is operating at a best-in-class level.

“This includes balancing internal investment with access to capabilities and capacities that are available with an experienced partner,” he said.